Yourgene Health (YGEN) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Dec 2018 07:00 AM
RNS
Half-year Results
07 Nov 2018 07:00 AM
RNS
Change of Name to Yourgene Health plc
05 Nov 2018 11:24 AM
RNS
Share Transfer
02 Nov 2018 07:00 AM
RNS
Directorate Change
25 Oct 2018 03:30 PM
RNS
Result of AGM
25 Oct 2018 07:00 AM
RNS
Holding(s) in Company
25 Oct 2018 07:00 AM
RNS
AGM Statement
22 Oct 2018 07:00 AM
RNS
Further re: Fundraise
12 Oct 2018 01:15 PM
RNS
Availability of Research Commentary
12 Oct 2018 07:00 AM
RNS
Trading Update and Notice of Results
05 Oct 2018 07:00 AM
RNS
Director's dealing and share option issue
04 Oct 2018 07:00 AM
RNS
$1 million collaboration agreement
03 Oct 2018 07:00 AM
RNS
Directorate change
02 Oct 2018 07:00 AM
RNS
Notice of AGM
01 Oct 2018 12:20 PM
RNS
Result of Fundraise
28 Sep 2018 05:41 PM
RNS
Proposed fundraise to raise approximately £2.5m
28 Sep 2018 05:40 PM
RNS
Full year results and half-year trading update
25 Sep 2018 11:31 AM
RNS
Holding(s) in Company
21 Sep 2018 04:10 PM
RNS
Holding(s) in Company
21 Sep 2018 07:00 AM
RNS
Holding(s) in Company
20 Sep 2018 09:30 AM
RNS
Senior Appointment & Anticipated Director Change
19 Sep 2018 11:05 AM
RNS
Second Price Monitoring Extn
19 Sep 2018 11:00 AM
RNS
Price Monitoring Extension
19 Sep 2018 07:00 AM
RNS
Legal Settlement & Licence Agreement with Illumina
11 Sep 2018 07:00 AM
RNS
Holding(s) in Company
07 Aug 2018 10:57 AM
RNS
Holding(s) in Company

Yourgene Health is an international molecular diagnostics group based in Manchester, UK, that develops genetic products and services for genomic medicine. Formerly known as Premaitha Health, Yourgene provides solutions for clinical, research, and pharmaceutical organizations, with a focus on non-invasive prenatal testing.

Its portfolio also includes products for oncology and infectious diseases, built on technologies like NGS and PCR. In July 2023, Yourgene Health was acquired by Novacyt.

Yourgene share price was listed under the ticker YGEN and delisted in 2023.

UK 100

Latest directors dealings